GenFleet Therapeutics (Shanghai) Inc. has called its 2025 annual general meeting for 11 May 2026 in Shanghai to vote on a broad slate of corporate and capital-management proposals.

Key agenda items include:

• 2025 Results Adoption – Shareholders will review and approve the 2025 Board Report, audited consolidated financial statements and full annual report.

• Board & Auditor Matters – Confirmation of directors’ remuneration: independent non-executive fees proposed at HK$0.50 million for Ms Christine Shaohua Lu-Wong and HK$0.28 million each for Dr Zhou Demin and Mr Li Bo, with no additional fees for executive or other non-executive directors. – Re-appointment of Ernst & Young as external auditor for 2026, with remuneration to be set by the Board.

• Capital Management Authorities – Repurchase Mandate: Board to receive authority to buy back up to 10% of issued shares (maximum 37.04 million H shares based on the 370.37 million shares outstanding as at 14 April 2026). – Issue Mandate: Board may issue, sell or transfer treasury shares of up to 20% of current issued capital (up to 74.07 million shares), with corresponding amendments to the Articles of Association.

• Governance Framework Updates – Abolishment of the supervisory committee structure is followed by revisions to four key governance documents: Rules of Procedure for Shareholders’ Meetings, Board Rules, Independent Non-executive Directors’ Working Rules and the Related Party Transaction Management System.

Voting logistics:

• Record date: 11 May 2026; share transfer registration closes 5 May 2026. • Proxy forms must be lodged at least 24 hours before the meeting. • All resolutions will be decided by poll.

GenFleet’s share capital currently comprises 338.03 million H shares and 32.34 million unlisted shares. The company stated it has no immediate plans to utilise either mandate but views the flexibility as beneficial for future strategic actions.